feeds.newsfilecorp.com · Nov 4, 2025
CSE Bulletin: Consolidation - MindBio Therapeutics Corp. (MBIO)
Toronto, Ontario--(Newsfile Corp. - Le 4 novembre/November 2025) - MindBio Therapeutics Corp. has announced
MB
NASDAQ · MBIO
Mustang Bio, Inc.
Healthcare · Biotechnology
$0.51
Down-$0.01 (-2.46%)
Updated Sep 12, 2026, 5:06 AM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 8.98M
- P/E ratio
- -15.09
- Dividend yield
- 0.00%
- 52-week range
- $0.52 – $1.85
- Volume
- 25.87K
- Avg. volume
- 109.51K
Price performance
MBIO price history
1M range · 20 trading sessions · Daily adjusted prices
MBIO closed at $0.51 after 20 trading sessions, down 14.54% for the selected period.
- Last close
- $0.51
- Period change
- -14.54%
- Period low
- $0.51
- Period high
- $0.59
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $0.5323 | $0.5496 | $0.507 | $0.5072 | 25.87K |
| Sep 10, 2026 | $0.5398 | $0.5398 | $0.52 | $0.52 | 20.62K |
| Sep 9, 2026 | $0.552 | $0.552 | $0.5235 | $0.5281 | 9.17K |
| Sep 8, 2026 | $0.54 | $0.5546 | $0.533 | $0.5412 | 22.53K |
| Sep 4, 2026 | $0.5533 | $0.5582 | $0.5322 | $0.5429 | 37.38K |
| Sep 3, 2026 | $0.5432 | $0.5609 | $0.5432 | $0.56 | 29.88K |
| Sep 2, 2026 | $0.5499 | $0.5499 | $0.5411 | $0.543 | 11.6K |
| Sep 1, 2026 | $0.5399 | $0.5488 | $0.5371 | $0.5481 | 18.14K |
| Aug 31, 2026 | $0.5382 | $0.5398 | $0.5327 | $0.5375 | 9.11K |
| Aug 28, 2026 | $0.55 | $0.55 | $0.5304 | $0.5376 | 20.26K |
| Aug 27, 2026 | $0.56 | $0.5601 | $0.5481 | $0.5501 | 33.18K |
| Aug 26, 2026 | $0.545 | $0.568 | $0.545 | $0.56 | 15.77K |
| Aug 25, 2026 | $0.551 | $0.5765 | $0.55 | $0.552 | 6.28K |
| Aug 24, 2026 | $0.5702 | $0.5783 | $0.55 | $0.5513 | 31.77K |
| Aug 21, 2026 | $0.5729 | $0.5787 | $0.57 | $0.5787 | 6.46K |
| Aug 20, 2026 | $0.56 | $0.5729 | $0.56 | $0.5729 | 14.17K |
| Aug 19, 2026 | $0.5525 | $0.5849 | $0.5525 | $0.574 | 10.12K |
| Aug 18, 2026 | $0.58 | $0.5963 | $0.5521 | $0.57 | 16.29K |
| Aug 17, 2026 | $0.5941 | $0.60 | $0.5941 | $0.5943 | 8.27K |
| Aug 14, 2026 | $0.5868 | $0.594 | $0.5868 | $0.5935 | 11.57K |
Latest MBIO news
The latest Smart Investors Daily articles mentioning MBIO.
Stock researchCompany · Overview
MBIO research
Overview
Company profile and research snapshot.
Company profile
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 16, 2024 | HC Wainwright & Co. | Buy | — |
| May 13, 2024 | HC Wainwright & Co. | Buy | — |
| Aug 24, 2023 | Cantor Fitzgerald | Overweight | — |
| Aug 16, 2023 | HC Wainwright & Co. | Buy | — |
| Aug 15, 2023 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
